The saphenous vein as a bypass conduit: The potential role of vascular nerves in graft performance

Current Vascular Pharmacology

Volumn 7, Issue 1, 2009, Pages 47-57

  Dashwood, Michael R ^a   Loesch, Andrzej ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bypass surgery; Graft failure; Neuropeptides; Neurotransmitters; Perivascular nerves; Saphenous vein

Indexed keywords

NEUROPEPTIDE; NEUROTRANSMITTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AUTONOMIC NERVOUS SYSTEM; BLOOD FLOW; BLOOD VESSEL INNERVATION; BLOOD VESSEL TONE; BODY POSTURE; CORONARY ARTERY BYPASS GRAFT; EXERCISE; EXPERIMENTAL MODEL; GRAFT FAILURE; GRAFT OCCLUSION; HEART MUSCLE ISCHEMIA; HUMAN; MITOGENICITY; NERVE CONDUCTION; NONHUMAN; ORTHOSTATIC BLOOD PRESSURE; PERIPHERAL NERVE; REVASCULARIZATION; REVIEW; SAPHENOUS VEIN; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE FIBER; SURGICAL INJURY; SURGICAL TECHNIQUE; VASCULAR SMOOTH MUSCLE; VEIN DIAMETER; VEIN INJURY; ANIMAL; INNERVATION; METABOLISM; METHODOLOGY; TRANSPLANTATION; VASCULAR PATENCY;

ANIMALS; CORONARY ARTERY BYPASS; GRAFT OCCLUSION, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; SAPHENOUS VEIN; TISSUE AND ORGAN HARVESTING; VASCULAR PATENCY;

EID: 61549110545     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109787354132     Document Type: Review

References (79)

1. Tsui JC, Dashwood MR. Recent strategies to reduce vein graft occlusion: a need to limit the effect of vascular damage. Eur J Vasc Endovasc Surg 2002; 23: 202-08.
2. Mehta D, Izzat MB, Bryan AJ, Angelini GD. Towards the prevention of vein graft failure. Int J Cardiol 1997; 62 (Suppl 1): S55.
3. Dashwood MR, Gibbins R, Mehta D, Bashar Izzat M, Angelini GD, Jeremy JY. Neural reorganisation in porcine vein grafts: a potential role for endothelin-1.Atherosclerosis 2000; 150: 43-3.
4. Amenta F, Cavallotti C, Dotta F, Ferrante F, Spinelli F, Vatrella F. The autonomic innervation of the human greater saphenous vein. Acta Histochem 1983; 72: 111-6.
5. Michaelis M, Goder R, Habler HJ, Janig W. Properties of afferent nerve fibres supplying the saphenous vein in the cat. J Physiol 1994; 47: 233-33.
6. Chen HI, Liu JC. Localization of sympathetic postganglionic neirons innervating the femoral-saphenous vein in cats. Neurosci Lett 1993; 155: 140-3.
7. Lemson MS, Tordoir JH, Daemen MJ, Kitslaar PJ. Intimal hyperplasia in vascular grafts. Eur J Vasc Endovasc Surg 2000; 19: 336-50.
8. Stick C, Hiedl U, Witzleb E. Eur J App Physiol.Venous pressure in the saphenous vein near the ankle during changes in posture and exercise at different ambient temperatures. Eur J Appl Physiol Occup Physiol 1993; 66: 434-8.
9. Rusch NJ, Wooldridge TA, Kulig CC, Almassi GH, Nicolosi AC, Olinger GN, Boerboom LE. Reactivity of human saphenous veins at arterial perfusion pressures. J Thorac Cardiovasc Surg 1995; 110(4 Pt 1): 1005-12.
10. Fabi F, Chiavarelli M, Argiolas L, Chiavarelli R, del Basso P. Evidence for sympathetic neurotransmission through presynaptic N-type calcium channels in human saphenous vein. Br J Pharmacol 1993; 110: 338-42.
11. Fabi F, Argiolas L, Ruvolo G, del Basso P. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane. Br J Pharmacol 1998; 124: 101-10.
12. Janssens W, Verhaeghe R. Modulation of the concentration of noradrenaline at the neuro-effector junction in human saphenous vein. Br J Pharmacol 1983; 79: 577-85.
13. Göthert M, Schlicker E, Hentrich F, Rohm N, Zerkowski HR. Modulation of noradrenaline release in human saphenous vein via presynaptic alpha 2-adrenoceptors. Eur J Pharmacol 1984; 102: 261-7.
14. Conant AR, Shackloth MJ, Oo AY, Chester MR, Simpson AW, Dihmis WC. Phenoxybenzamine treatment is insufficient to prevent spesm in the radial artery: the effect of other vasodilators. J Thorac Cardiovasc Surg 2003; 126: 448-54.
15. Chester AH, Bodelsson M, Arnelko Nobin B, Tadjkarimi S, Tornenbrandt K, et al. Characterization of 5-HT receptors in human saphenous vein, implications for patency of bypass grafts. App J Cardiol 1990; 5: 51-9.
16. Razzaque Z, Pickard JD, Ma QP, Shaw D, Morrison K, Wang T, et al. 5-HT1B-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan. Br J Clin Pharmacol 2002; 53: 266-74.
17. Wurch T, Palmier C, Colpaert FC, Pauwels PJ. Recombinant saphenous vein 5-HT1B receptors of the rabbit: comparative pharmacology with human 5-HT1B receptors. Br J Pharmacol 1997; 120: 153-59.
18. Dahm PL, Bodelsson M, Törnebrandt K, Muddle JR, Sykes RM, Yacoub M, et al. Binding of 3H-5-hydroxytryptamine to human coronary artery and bypass graft vessels. Cardiovasc Res 1996; 31: 800-06.
19. Racchi H, Irarrázabal MJ, Howard M, Morán S, Zalaquett R, Huidobro-Toro JP. Adenosine 5'-triphosphate and neuropeptide Y are co-transmitters in conjunction with noradrenaline in the human saphenous vein. Br J Pharmacol. 1999; 126: 1175-185.
20. Flavahan NA, Rimele TJ, Cooke JP, Vanhoutte PM. Characterization of postjunctional alpha-1 and alpha-2 adrenoceptors activated by exogenous or nerve-released norepinephrine in the canine saphenous vein. J Pharmacol Exp Ther 1984; 230: 699-05.
21. Komori K, Flavahan NA, Miller VM, Vanhoutte PM. Electrophysiological analysis of adrenergic neurotransmission and its modulation by chronic denervation in canine saphenous veins. J Pharmacol Exp Ther 1990; 252: 1197-201.
22. Verbeuren TS, Lorenz RR, Aarhus LL, Shepherd JT, Vanhoutte PM. Prejunctional beta-adrenoceptors in human and canine saphenous veins. J Autonom Nerv Syst 1983; 8: 261-71.
23. Humphrey PP, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates LH, et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988; 4: 1123-32
24. Vayssettes-Courchay C, Ragonnet C, Cordi AA, Verbeuren TJ. In vivo analysis of adrenergic and serotoninergic constrictions of the rabbit saphenous vein. Eur J Pharmacol 2000; 408: 277-88.
25. Martin GR, MacLennan SJ. Analysis of the 5-HT receptor in rabbit saphenous vein exemplifies the problems of using exclusion criteria for receptor classification. Naunyn Schmiedebergs Arch Pharmacol 1990; 342: 111-9.
26. MacDonald A, Daly CJ, Bulloch JM, McGrath JC. Contribution of alpha 1-adrenoceptors and P2x-purinoceptors to neurotransmission in several rabbit isolated blood vessels: role of neuronal uptake and autofeedback. Br J Pharmacol 1992; 105: 347-54.
27. Monos E, Lorant M, Feher E. Influence of long-term experimental orthostatic body position on innervation density in extremity vessels. Am J Physiol Heart Circ Physiol 2001; 281: H1606-12.
28. Bevan RD. Trophic effects of peripheral adrenergic nerves on vascular structure. Hypertension 1984; 6: 19-6.
29. Folkow B. Neurotrophic effects on the vascular bed. Acta Med Scand Suppl 1983; 672: 95-9.
30. Lee RM, Gzik DJ. Sympatholytic interventions and vascular remodelling. Basic Res Cardiol 1991; 86: 55-4.
31. McGeachie JK, Meagher S, Prendergast FJ. Vein-to-artery grafts: the long-term development of neo-intimal hyperplasia and its relationship to vasa vasorum and sympathetic innervation. Aust N Z J Surg 1989; 59: 59-5.
32. Heistad DD, Marcus ML, Martins JB. Effects of neural stimuli on blood flow through vasa vasorum in dogs. Circ Res 1979; 45: 615-20.
33. Herbst WM, Eberle KP, Ozen Y, Hornstein OP. The innervation of the great saphenous vein: an immunohistochemical study with special regard to regulatory peptides. Vasa 1992; 21: 253-7.
34. Ohhashi A, Ohhashi T. Effects of aortic pressure and vasoactive agents on the vascular resistance of the vasa vasorum in canine isolated thoracic aorta. J Physiol 1992; 453: 233-45.
35. Tsui JC, Souza DS, Filbey D, Karlsson MG, Dashwood MR. Localization of nitric oxide synthase in saphenous vein grafts harvested with a novel "no-touch" technique: potential role of nitric oxide contribution to improved early graft patency rates. J Vasc Surg 2002; 35: 356-62.
36. Souza D. A new no-touch preparation technique. Scand J Thor Cardiovasc Surg 1996; 30: 41-4.
37. Barker SG, Talbert A, Cottam S, Baskerville PA, Martin JF. Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thromb 1993; 13: 70-7.
38. Rothe CF. Venous system: physiology of the capacitance vessels. In: Hanbook of Physiology: Section 2: The cardiovascular system III Sheperd JT, Abboud FM, Bethesda MD eds., American Physiolgy Society, 1983 pp 397-52.
39. Crotty TP. The role of vasa vasorum in atherosclerosis. Med Hypoth 1989; 28: 233-3.
40. Crotty TP. The vasa vasorum and the paradox of beta-blocker therapy. Med Hypoth 1992; 37: 191-97.
41. Amenta F, Mione MC, Napoloeone P. The autonomic innervation of the vasa nervorum. J Neural Transm 1983; 58: 291-97.
42. Franco-Cereceda A, Rydh M, Lou YP, Dalsgaard CJ, Lundberg JM. Endothelin as a putative sensory neuropeptide in the guinea-pig: different properties in comparison with calcitonin gene-related peptide. Regul Pept 1991; 32: 253-65.
43. Giaid A, Gibson SJ, Ibrahim BN, Legon S, Bloom SR, Yanagisawa M, et al. Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci USA 1989; 86: 7634-38.
44. Loesch A, Milner P, Burnstock G. Endothelin in perivascular nerves. An electron- immunocytochemical study of rat basilar artery. NeuroReport 1998; 9: 3903-06.
45. Loesch A, Gajkowska B, Dashwood MR, Fioretto ET, Gagliardo KM, de Lima AR, et al. Endothelin-1 and endothelin receptors in the basilar artery of the capybara. J Mol Hist 2005; 36: 25-4.
46. Mickey I, Kilford L, Kingsbury A, Loesch A. Endothelin in the middle cerebral artery: a case of multiple system atrophy. Histochem J 2002; 34: 469-77.
47. Loesch A, Burnstock G. Endothelin in human cerebrovascular nerves. Clin Sci 2002; 103: 4045-75.
48. Zochodne DW, Ho LT, Gross PM. Acute endoneurial ischemia induced by epineurial endothelin in the rat sciatic nerve. Am J Physiol 1992; 263(6 Pt 2): H1806-10.
49. Cameron NE, Dines KC, Cotter MA The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats. Diabetologia 1994; 37: 1209-15.
50. Stevens EJ, Tomlinson DR.Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br J Pharmacol 1995; 115: 373-9.
51. Dashwood MR, Thomas PK. Neurovascular [125I]-ET-1 binding sites on human peripheral nerve. Endothelium 1997; 5: 119-23.
52. Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YY, Zucker IH. Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1906-13.
53. Jeremy JY, Dashwood MR, Timm M, Izzat MB, Mehta D, Bryan AJ, et al. Nitric oxide synthase and adenylyl and guanylyl cyclase activity in porcine interposition vein grafts. Ann Thorac Surg 1997; 63: 470-6.
54. Isaka M, Kudo A, Imamura M, Kawakami H, Yasuda K. Endothelin receptors, localized in sympathetic nerve terminals of the heart, modulate norepinephrine release and reperfusion arrhythmias. Basic Res Cardiol 2007; 102: 154-62.
55. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
56. Tsui JC, Souza DS, Filbey D, Bomfim V, Dashwood MR. Preserved endothelial integrity and nitric oxide synthase in saphenous vein grafts harvested by a 'no-touch' technique. Br J Surg. 2001; 88: 1209-15.
57. Wheater PR, Burkitt HG, Daniels VH. Functional Histology 1987, Churchill Livingstone, UK.
58. De Meyer GR, Bult H, Martin JF, Van Hoydonck AE, Herman AG. The effect of a developing neo-intima on serotonergic and adrenergic contractions. Eur J Pharmacol 1990; 187: 519-24.
59. Origuchi N, Shigematsu H and Muto T. Anplag, a selective 5-HT2 receptor antagonist, reduces stenosis induced by balloon injury in the hypercholesterolaemic rabbit. Int Angio 1997; 16: 204-09.
60. Massey MF, Davies MG, Svedsen E, Klyachkin ML, Schwarz LB, Barber L, et al. Reduction of experimental vein graft intimal hyperplasia by ketanserin. J Surg Res 1993; 54: 530-38.
61. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produced both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266(Pt 1): L46-2.
62. MacLean MR. Pulmonary hypertension and the serotonin hypothesis: where are we now? Int J Clin Pract 2007; 61 (Suppl 156): 27-1.
63. Blaes N, Biossel JP. Growth-stimulating effect of catecholamines on rat aortic smooth muscle cells in culture. J Cell Physiol 1983; 116: 167-72.
64. Hu ZW, Shi XY, Lin RZ, Chen J, Hoffman BB. Alpha 1-adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. J Pharmacol Exp Ther 1999; 290: 28-7.
65. O'Malley MK, McDermott EW, Mehigan D, O'Higgins NJ. Role for prazosin in reducing the development of rabbit intimal hyperplasia after endothelial denudation, Br J Surg 1989; 76: 936-38.
66. Fingerle J, Sanders KH, Fotev Z. Alpha 1-receptor antagonists urapidil and prazosin inhibit neointima formation in rat carotid artery induced by balloon catheter injury. Basic Res Cardiol 1991; 86(Suppl 1): 75-1.
67. Zhang H, Faber JE. Trophic effect of norepinephrine on aterial intima-media and adventitia is augmented by injury and mediated by different alpha 1 -adrenoceptor subtypes. Circ Res 2001; 89: 815-22.
68. Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res 2004; 94: 37-5.
69. Erami C, Zhang H, Tanoue A, Tsujimoto G, Thomas SA, Faber JE. Adrenergic catecholamine trophic activity contributes to flow-mediated arterial remodelling. Am J Physiol Heart Circ Physiol 2005; 289: H744-53.
70. Ohlstein EH, Douglas SA, Sung CP, Yue TL, Louden C, Arleth A, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 90: 6189-93.
71. Patel MK, Chan P, Betteridge LJ, Schachter M, Sever PS. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol 1995; 25: 652-7.
72. Johnson R, Webb JG, Newman WH, Wang Z. Regulation of human vascular smooth muscle cell migration by beta-adrenergic receptors. Am Surg 2006; 72: 51-4.
73. Yasunari K, Kohno M, Hasuma T, Horio T, Kano H, Yokokawa K, Minami M, Yoshikawa J. Dopamine as a novel antimitogen and antiproliferative factor of vascular smooth muscle cells through dopamine D1-like receptors. Arterioscler Thromb Vasc Biol 1997; 17: 3164-73.
74. Dashwood MR, Timm M, Kaski J-C, Murday AJ, Madden BP. 125I-ET-1 binding to perivascular nerves of human epicardial coronary arteries. Endothelium 1996; 4: 231-4.
75. Dashwood MR, Timm M, Muddle JR, Ong ACM, Tippins JR, Parker R, et al. Regional variations in endothelin-1 and its receptor subtypes in human coronary vasculature: pathophysiological implications in coronary disease. Endothelium 1998; 6: 61-70.
76. Dashwood MR, Jeremy JY, Mehta D, Izzat MB, Timm M, Bryan AJ, et al. Endothelin-1 and endothelin receptors in porcine saphenous vein-carotid artery grafts. J Cardiovasc Pharmacol 1998; 31(Suppl 1): S328-30.
77. Mehta D, George SJ, Jeremy JY, Izzat MB, Southgate KM, Bryan AJ, et al. External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat Med 1998; 4: 235-9.
78. Dashwood MR, Angelini GD, Wan S, Yim A, Mehta D, Izzat MB, et al. Does external stenting reduce porcine vein-graft occlusion via an action on vascular nerves? J Card Surg 2002; 17: 556-60.
79. Dashwood MR, Angelini GD, Mehta D, Jeremy JY, Muenter K, Kirchengast M. Effect of angioplasty and grafting on porcine vascular nerves: a potential neurotropic role for endothelin-1. J Anat 1998; 192: 435-7.